The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

Wide Open Agriculture confirms multi-billion dollar skin care potential of lupin oil product

Wide Open Agriculture’s lupin oil product has been confirmed for both safety and its skin hydration…

Paradigm completes Phase 3 enrolment as Zilosul trial moves toward interim analysis

Paradigm Biopharmaceuticals has completed enrolment in its Phase 3 knee osteoarthritis trial, with top-line results expected…

AFT Pharmaceuticals identifies multi-billion-dollar market potential with expanding portfolio

AFT Pharmaceuticals has unveiled new growth opportunities in its research and development portfolio and within its…

Hydrix secures A$3.4M US medical robotics contract with Remedy Robotics

Hydrix has secured a $3.4M contract with Remedy Robotics to support its next-generation N1 robotic platform…